STIM Neuronetics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why STIM matters now
Neuronetics, Inc. (STIM) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.76 with +6.02% on the session and $122.5M in market capitalization; recent performance reads 1-month +4.24% and YTD -10.87%.
The latest financial table shown here is Q1 2026, with revenue of $34.5M, net income of $-10.8M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.9%.
The latest indexable market news headline is "Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Madryn Asset Management, LP filing J-Other. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.45
P/S
0.56
EV/EBITDA
-6.14
DCF Value
$-51.16
FCF Yield
-15.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.0%
Operating Margin
-19.4%
Net Margin
-24.5%
ROE
-164.7%
ROA
-29.6%
ROIC
-28.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $34.5M | $-10.8M | $-0.16 |
| Q4 2025 | $41.8M | $-7.2M | $-0.10 |
| FY 2025 | $149.2M | $-39.0M | $-0.59 |
| Q3 2025 | $37.3M | $-9.0M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.04
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.